Advertisement
Advertisement
CRON
Cronos Group Inc. Common Share
3.17
USDSponsored
+0.09
+2.92%
Aug 12, 15:51 UTC -4
Closed
Pre-Market
3.16
-0.01
-0.32%
CRON Earnings Reports
Positive Surprise Ratio
CRON beat 23 of 39 last estimates.
59%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$50.46M
/$0.02
Implied change from Q2 26 (Revenue/ EPS)
-4.81%
/-33.33%
Implied change from Q3 25 (Revenue/ EPS)
+38.85%
/-75.00%
Cronos Group Inc. Common Share earnings per share and revenue
On Aug 06, 2026, CRON reported earnings of 0.03 USD per share (EPS) for Q2 26, Inline the estimate of 0.00 USD, resulting in a 0.00% surprise. Revenue reached 53.01 million, compared to an expected 45.08 million, with a 17.57% difference. The market reacted with a +12.87% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of 0.02 USD, with revenue projected to reach 50.46 million USD, implying an decrease of -33.33% EPS, and decrease of -4.81% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Silence Therapeutics Plc - ADR
Report Date
Aug 10, 2026 For Q2 26
Estimate
-Actual
-$0.26
Surprise
-
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
Heron Therapeutics, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.01
Actual
-$0.03
Surprise
-394.12%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Cronos Group Inc. Common Share's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Cronos Group Inc. Common Share reported EPS of $0.03, missing estimates by 0%, and revenue of $53.01M, 17.57% above expectations.
How did the market react to Cronos Group Inc. Common Share's Q2 2026 earnings?
The stock price moved up 12.87%, changed from $2.72 before the earnings release to $3.07 the day after.
When is Cronos Group Inc. Common Share expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Cronos Group Inc. Common Share's next earnings report?
Based on 3
analysts, Cronos Group Inc. Common Share is expected to report EPS of $0.02 and revenue of $50.46M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement